IMNN News - Candlesense

IMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

(NASDAQ:IMNN) LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today annou...

Investor

13 days ago

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement

LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Com...

What are the potential downstream effects on upcoming clinical‑trial milestones and financing needs now that Nasdaq delisting risk is removed? Does this listing event change market perception of IMUNON’s operational stability versus its peers in the biotech sector? How will the regained compliance affect IMNN’s short‑term price volatility and liquidity on Nasdaq?

Regulation

18 days ago